Australia is backing health innovation industries to build future economy
Announced in the federal budget last night, the 21st century National Medical Industry Growth Plan will deliver $1.3 billion to support Australia as a global health innovation leader in medical technology, biotechnology and pharmaceuticals while improving health outcomes for…
New BioMelbourne Network Board Appointment – David Herd
The BioMelbourne Network Board was delighted to welcome David Herd as new Board Director at the most recent board meeting. “BioMelbourne is a very active and positive contributor to shaping many aspects of our Industry and I am…
BioMelbourne Network gives State Budget 6/10 for the health innovation industry
BioMelbourne Network CEO Dr Krystal Evans welcomes the State Government of Victoria’s Budget yesterday, noting the significant investment in digital infrastructure, the Heart Hospital and the ongoing operational support for the Melbourne Biomedical Precinct. However, these initiatives are…
BioMelbourne Network Policy Principles – 2018 State Election
May 2018 The biotechnology, medical technology and pharmaceutical sector in Victoria is vibrant and growing but yet to reach its full potential contribution to the Victorian economy. Historical support from governments has allowed the sector to grow, now…
AusBiotech announces leadership changes
Mr Glenn Cross retires as AusBiotech’s CEO, and Ms Lorraine Chiroiu appointed as new CEO effective early July 2018 Mr Glenn Cross retirement AusBiotech Chairman, Julie Phillips, has tonight announced that Mr Glenn Cross has decided to retire…
Bioforum Data Focused CRO Opens New Melbourne Office
Company provides local services for companies running R&D activities in Australia Bioforum – the Data Focused CRO and the leading Medidata partner in Israel, servicing research and academic institutes, pharma companies, CROs and startups locally and globally for…
$10m in funding awarded to 11 projects to boost health innovation
MTPConnect – the Australian Government’s Medical Technology, Biotechnology, and Pharmaceutical (MTP) Industry Growth Centre – and the Minister for Health, the Hon Greg Hunt MP, today announced the first 11 recipients of $10 million investment from the Australian…
Prota Therapeutics partners with world-leading bioscience company, Chr. Hansen
Prota Therapeutics partners with leading global bioscience company, Chr. Hansen, to progress the development of oral immunotherapies to treat food allergies. The partnership will assess the world’s best documented probiotic strain LGG® in a Phase III clinical trial…
Future Plans Announced for Digital Health CRC
A $200+ million opportunity to transform health delivery: improving health outcomes; reducing waste in the health system; building businesses and jobs. The new Digital Health CRC (Cooperative Research Centre) will invest over $200 million to develop and test…
Cancer Therapeutics CRC Appoints New CEO
Cancer Therapeutics CRC (CTX), a small molecule oncology drug discovery and development group partnered with some of Australia’s pre-eminent medical research institutions, is pleased to announce the appointment of Brett Carter as Chief Executive Officer. Brett will succeed…
Immutep Raises A$6.85M Through Institutional Placement
Read ASX Announcement Here • A$6.85m raised through share institutional placement to drive immuno-oncology development programs • Placement of new ordinary shares to leading Australian healthcare institutional investors Platinum Asset Management and Australian Ethical Investment, U.S. healthcare institutional…
Immutep Enters Into Clinical Trial Collaboration and Supply Agreement with MSD
Read ASX Announcement Here Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) has announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as…
